item management s discussion and analysis of financial condition and results of operations for the three years ended december   and results of operations net income loss net income in increased to  compared to a net loss of  in and net income of  in income before income taxes and unusual items increased to  in compared to  in and  in including unusual items  income before income taxes was  in compared to  in and  in income before income taxes in includes a charge to earnings of  related to the restructuring of the company s non allograft bone tissue operations located in leiden  the netherlands 
income before income taxes in includes the receipt of note repayments on a fully reserved note from a major client of  and a charge to earnings of  resulting from the termination of a distribution agreement for trauma implant products 
see provision for restructuring and provision for termination of a distribution agreement included elsewhere in item in  income tax expense was reduced by the recognition of net deferred tax assets resulting primarily from temporary differences which reversed during the year and the realization of tax benefits associated with federal and state tax net operating loss carryforwards and tax credits 
see income tax provision included elsewhere in item the table below shows the impact of these items income before income taxes and unusual items    unusual items provision for restructuring  note repayments from major clients  provision for termination of distribution agreement  income before income taxes    recognition of net deferred tax assets  income tax provision    net income loss    the company provides information concerning income before taxes and unusual items because it enhances an investor s understanding of the company s operating performance and cash flows 
income before taxes and unusual items excludes significant components of income and expense which impact company financial performance  and should not be considered an alternative to income before income taxes  net income loss  or any other measure of financial performance required by gaap  and should be read in conjunction with the consolidated financial statements of the company included in a separate section of this annual report commencing on page f the following is a discussion of factors which affected results of operations for the years ended december   and net revenues net revenues in increased to  from  in net revenues in were higher than revenues of  domestic revenues increased to  in compared to  in domestic revenues in were higher than revenues of  the increase in domestic revenues resulted principally from increased demand for the company s proprietary grafton r dbm allograft processing services  which increased in and in  compared to the respective prior years 
non allograft bone tissue foreign revenues decreased to  in compared to  in non allograft bone tissue foreign revenues in were lower than revenues of  the decline in is attributable to the loss of grant revenues from the dutch government  which were  in  as a result of the discontinuance of the company s polyactive tm polymer research and development program 
during  the company licensed out the patents and technology related to polyactive tm and received an upfront payment of  which partially offset the decline in grant revenues 
additionally  non allograft bone tissue foreign revenues in were unfavorably impacted as a result of the strength of the us dollar compared to the dutch guilder 
however  the impact on consolidated net revenues was approximately 
the decline in resulted from decreases in ceramic spray coating services  ceramic products and grant revenues 
during  and  two of the company s allograft bone tissue clients  mtf and arc  accounted for and  and and and  respectively  of revenues 
effective in  the company entered into new long term exclusive processing agreements with mtf and arc 
costs of services and products costs of services as a percentage of service revenues was in  in and in the decline in costs as a percentage of revenues results from ashift in revenue mix toward services with higher gross margins  operating efficiencies resulting from increased volume and an increase in fees charged to the company s customers for certain allograft processing services 
cost of products as a percentage of product revenues was in  in and in the decline in costs as a percentage of revenue in results primarily from a shift in product mix toward products with higher gross margins 
the increase in costs in as a percentage of revenues resulted principally from an increase in product liability insurance premiums associated with spinal implant products distributed by the company 
marketing  general and administrative expenses marketing  general and administrative expenses increased  or in and  or in the increases are primarily attributable to expanded marketing and promotional activities associated with the continued expansion of the business  increased agent commissions directly related to the increase in grafton r dbm revenues and increased administrative costs  principally outside professional services 
research and development expenses research and development expenses in decreased  or  to  from  in the decline results principally from the discontinuance of the company s polyactive tm polymer research and development program in the fourth quarter of see provision for restructuring 
research and development expenses in increased  or to  from  in the increase was primarily attributable to increased spending associated with the development of additional allograft bone tissue forms which were introduced into the market during  expansion of the company s viral inactivation process to a broader range of allograft bone tissue and the development of polyactive tm products 
provision for restructuring in october  the company announced a plan to restructure its non allograft bone tissue operations located in leiden  the netherlands in order to focus those operations on i the revenue and profit generating activities of providing ceramic and titanium spray coating services and ceramic products to the orthopaedic and dental markets and ii to pursue oem business opportunities for those technologies 
in connection with the restructuring  the company discontinued its polyactive tm polymer research and development program 
as a result of the restructuring  the company recorded a pre tax restructuring charge of  which included  for employee termination costs   for write off ofequipment  intangible assets and inventory   for costs associated with the planned sub leasing of office space in leiden on which the company has a long term lease and  for other contractual obligations 
see note of notes to consolidated financial statements 
provision for termination of distribution agreement in june  the company terminated its distribution agreement for trauma implant products with its supplier  aap  gmbh  of berlin  germany 
as a result of this termination the company recorded a pre tax charge to earnings of  which included  for inventory write offs   for employee termination costs and  for legal fees 
revenues from marketing trauma products were not material in see note of notes to consolidated financial statements 
other income expense in  other income increased by  compared to due to higher invested cash and lower outstanding debt balances 
in  other income decreased by  compared to other income in included the receipt of  of note repayments on a fully reserved note from a major client 
see note of notes to consolidated financial statements 
income tax provision the company s effective income tax rate declined to in from in the high effective income tax rate in was principally due to foreign losses for which no current tax benefits were available 
the effective income tax rate was in due to the company s recognition of net deferred tax assets of  related to i the realization of  of tax benefits from temporary differences which reversed during the year  and ii the company s assessment that it would generate sufficient future us taxable income to realize  of deferred tax benefits associated with certain federal and state net operating loss carryforwards and tax credits 
see note of notes to consolidated financial statements 
liquidity and capital resources at december   the company had cash and short term investments of  compared to  at december  working capital increased  to  at december  compared to  at december  accounts receivable at december  increased by  from  due to the strong fourth quarter revenue increase 
net cash provided by operations was  in  compared to  in the increase resulted primarily from the company s improved earnings in cash used for capital expenditures increased to  in from  in as the company continues to invest in facilities and equipment needed for current and future business requirements 
the company expects capital expenditures to be approximately equivalent to capital expenditures 
the company has not yet determined the amount of any capital expenditures to be incurred in connection with the proposed processing facility described in item properties or whether such capital expenditures will be financed through a lease  the company s current credit facilities or its cash reserves 
net cash provided by financing activities was  in compared to net cash used in financing activities of  in the increase results principally from cash proceeds received from stock option exercises 
the company has a loan and security agreement with a us bank which provides for borrowings of up to  under a revolving line of credit and  under an equipment line of credit 
at december    was outstanding under the equipment line of credit and there were no borrowings outstanding under the revolving line of credit 
the company also has a line of credit with a dutch bank which provides for borrowings of up to dfl  or approximately  at the december  exchange rate 
analysis of the company s cash position and anticipated cash flow indicated that it most likely would not be necessary to utilize a significant portion of this line of credit in and  therefore  the company agreed with the bank to limit its borrowings in  if any  to no more than dfl  or approximately  at the december  exchange rate 
additionally  in connection with the leiden facility lease  the company is required to maintain a declining bank guarantee which reduced the current amount available for borrowings to dfl  or approximately  at the december  exchange rate 
at december   there were no borrowings outstanding under this credit line 
see note of notes to consolidated financial statements 
at december  certain of the company s foreign subsidiaries have net operating loss carryforwards aggregating  at the december  exchange rate  with no expiration date   expiring through 
see note of notes to consolidated financial statements 
the company believes that its cash and cash equivalents  short term investments and available lines of credit  together with anticipated future cash flow from operations will be sufficient to meet its near term requirements  but may not be adequate to fully develop and commercialize all products currently under development by the company 
further  from time to time  the company may seek additional funds through equity or debt financing 
however  there can be no assurance that such additional funds will be available to the company  or if available  that such funds will be available on terms favorable to the company 
impact of inflation and foreign currency exchange fluctuations the results of the company s operations for the periods discussed have not been significantly affected by inflation or foreign currency fluctuations 
year the company regularly evaluates its computer hardware and software applications to determine the adequacy of such systems to support the company s business operations 
as a result of such evaluation  the company identified changes that were required  and commenced implementation of a new fully integrated computerized management information systems  which is expected to be fully operational in the new system is year compliant  and accordingly  the company does not anticipate a disruption to its business operations or those of its clients 
since the new software is being implemented to support the company s business operations  there is no incremental cost associated with year compliance 
item a 
quantitative and qualitative disclosures about market risk not applicable 

